Response to letter regarding article ‘Fingolimod effects on left ventricular function in multiple sclerosis’

Abstract

Get full access to this article

View all access options for this article.

References

Calabresi

Radue

Goodin

. Safety and efficacy of fingolimod in patients with relapsing–remitting multiple sclerosis (FREEDOMS II): A double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Neurol 2014; 13: 545–556.

Racca

Di Rienzo

Cavarretta

. Fingolimod effects on left ventricular function in multiple sclerosis. Mult Scler 2016; 22: 201–211.

Brinkmann

Baumruker

. Pulmonary and vascular pharmacology of sphingosine 1-phosphate. Curr Opin Pharmacol 2006; 6: 244–250.